The global over-the-counter (OTC) analgesics market size accounted for USD 30.76 billion in 2024, grew to USD 31.89 billion in 2025 and is expected to be worth around USD 44.23 billion by 2034, registering a healthy CAGR of 3.70% between 2024 and 2034. The North America over-the-counter (OTC) analgesics market size is calculated at USD 13.53 billion in 2024 and is estimated to grow at a fastest CAGR of 3.81% during the forecast period.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Over-the-counter (OTC) Analgesics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Over-the-counter (OTC) Analgesics Market Revenue and Volume, by Type of Drug, 2024-2034
8.1.1. Acetaminophen
8.1.1.1. Market Revenue and Volume Forecast (2024-2034)
8.1.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
8.1.2.1. Market Revenue and Volume Forecast (2024-2034)
8.1.3. Salicylates
8.1.3.1. Market Revenue and Volume Forecast (2024-2034)
8.1.4. Other Analgesics
8.1.4.1. Market Revenue and Volume Forecast (2024-2034)
9.1. Over-the-counter (OTC) Analgesics Market Revenue and Volume, by Distribution Channel, 2024-2034
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Volume Forecast (2024-2034)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Volume Forecast (2024-2034)
9.1.3. Online Pharmacies
9.1.3.1. Market Revenue and Volume Forecast (2024-2034)
9.1.4. Other Distribution Channels
9.1.4.1. Market Revenue and Volume Forecast (2024-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.1.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.2.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.5.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Type of Drug (2024-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Distribution Channel (2024-2034)
11.1. Bayer AG
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Boehringer Ingelheim International GmbH
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Johnson & Johnson
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Haleon PLC
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Endo International PLC
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Reckitt Benckiser Group PLC
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sanofi SA
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Sun Pharmaceutical Industries Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Teva Pharmaceutical Industries Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Viatris Inc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample